These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19253469)

  • 1. [Electroencephalographic study of children with attention deficit hyperactivity disorder before and after treatment with strattera].
    Nikishina IS; Chutko LS; Surushina SIu; Iakovenko EA; Kropotov IuD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(12):60-2. PubMed ID: 19253469
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effectiveness of strattera in children and adolescents with attention deficit hyperactivity disorder].
    Vakula IN; Vasianina IuSh; Gorbunova ZKh; Nikiforova EIu; Ponomarenko EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(8):42-4. PubMed ID: 19738568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The treatment of attention deficit hyperactivity disorder with comorbid tic hyperkinesis].
    Chutko LS; Surushkina SIu; Nikishena IS; Iakovenko EA; Lapshina OV; Anisimova TI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(2):66-8. PubMed ID: 18646384
    [No Abstract]   [Full Text] [Related]  

  • 4. [Atomoxetine (strattera) in the treatment of attention deficit hyperactivity syndrome].
    Ershova A
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(10):87-91. PubMed ID: 19097312
    [No Abstract]   [Full Text] [Related]  

  • 5. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients.
    Clemow DB
    Postgrad Med; 2014 Sep; 126(5):196-8. PubMed ID: 25420287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Takita Y; Goto T; Ichikawa H; Saito K; Matsumoto H; Tanaka Y
    Psychiatry Clin Neurosci; 2011 Feb; 65(1):55-63. PubMed ID: 21265936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent Raynaud's phenomenon developing from use of atomoxetine in a girl.
    Gökçen C; Kutuk MO; Coşkun Ş
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):428-30. PubMed ID: 23952193
    [No Abstract]   [Full Text] [Related]  

  • 8. [Atomoxetine and piracetam in the treatment of attention deficit hyperactivity disorder in children].
    Zavadenko NN; Suvorinova NIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):43-7. PubMed ID: 18833117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent camptocormia associated with atomoxetine in a child with attention-deficit/hyperactivity disorder.
    Bhattacharya A; Praharaj SK; Sinha VK
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):596-7. PubMed ID: 25469421
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms.
    van der Meer JM; Harfterkamp M; van de Loo-Neus G; Althaus M; de Ruiter SW; Donders AR; de Sonneville LM; Buitelaar JK; Hoekstra PJ; Rommelse NN
    J Clin Psychopharmacol; 2013 Dec; 33(6):824-7. PubMed ID: 24018545
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.
    Saylor K; Williams DW; Schuh KJ; Wietecha L; Greenbaum M
    Curr Med Res Opin; 2010 Sep; 26(9):2087-95. PubMed ID: 20642391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
    Sasané R; Hodgkins P; Meijer W
    Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast vs. slow switching from stimulants to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder.
    Cardo E; Porsdal V; Quail D; Fuentes J; Steer C; Montoya A; Anand E; Escobar R
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):252-61. PubMed ID: 23683140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
    Fuentes J; Danckaerts M; Cardo E; Puvanendran K; Berquin P; De Bruyckere K; Montoya A; Quail D; Escobar R
    J Clin Psychopharmacol; 2013 Dec; 33(6):766-74. PubMed ID: 23963057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
    Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder.
    Hergüner S; Hergüner A
    J Clin Psychopharmacol; 2012 Apr; 32(2):302-3. PubMed ID: 22388168
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
    Wehmeier PM; Dittmann RW; Schacht A; Minarzyk A; Lehmann M; Sevecke K; Lehmkuhl G
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):813-30. PubMed ID: 18315453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Attention deficit hyperactivity disorder: clinical heterogeneity and possibilities of therapy].
    Chutko LS; Surushkina SIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(8):75-80. PubMed ID: 19115509
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.